# NIH Reporter #5R01AG088141-02

Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People with Down Syndrome

**Recipient:** Brigham and Women's Hospital, Boston, MA, United States

**Award Amount:** $801,611.00
**Ceiling:** $801,611.00

**Awarded:** September 09, 2026

**Identifier:** 5R01AG088141-02

This NIH-funded project studies the safety and effects of NMN to address Alzheimer's Disease in adults with Down syndrome through a clinical trial.

### Description

A phase 1, randomized, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Nicotinamide mononucleotide (NMN) in adults with Down syndrome, aiming to prevent or reverse Alzheimer's Disease progression.

[View original record](https://reporter.nih.gov/search/0C83gI3MXki4-tEhFD4UKQ/project-details/11411154)